Novartis Ups Forecast on Lack of Diovan Competitor

Novartis Ups Forecast on Lack of Diovan Competitor Play

July 17 (Bloomberg) -- Novartis AG raised its full-year forecast as generic competition for the Diovan blood-pressure drug failed to materialize in the U.S. Sam Fazeli reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus